studies of antigen presentation of peptides by MHC class I molecules
MHC I 类分子对肽的抗原呈递的研究
基本信息
- 批准号:05454204
- 负责人:
- 金额:$ 4.35万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for General Scientific Research (B)
- 财政年份:1993
- 资助国家:日本
- 起止时间:1993 至 1994
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
1.We found that assembly rate of HLA-B35 molecules is faster than that of HLA-B51 molecules. One can speculate that the difference of peptide binding affinity to these HLA class I molecules result in that of assembly rate. To investigate peptide binding to HLA class I molecules, we established novel binding assay using RMA-S cells trasnfected with HLA class I genes. Analysis of binding of peptides carrying anchor residues of HLA-B35 or B51 to these HLA class I molecules indicate that the peptide binding affinity to HLA-B51 is significantly weaker than that to HLA-B35. These findings imply that the difference of assembly rate may result from that of peptide binding to these HLA class I molecules in endoplasmic reticurum.2.In order to clarify self-peptides recognized by T cells, we attempted to isolate allopeptides recognized by HLA-B51 alloreactive CTL.In HPLC fraction of peptides isolated from purified HLA-B51 molecules, a TAP dependent peptide recognized by one HLA-B51 alloreactive CTL clone was detected. This approach is very useful for studies of antigen presentation and T cell recognition.3.Polymorphism and antigen presentation of human minor histocompatibility (hmH) antigens were studied using hmH specific CTL clones. The CTL clones killed most target cells expressing HLA-B35, while they failed to kill the cells expressing HLA-B35 subtypes. Since the specific hmH peptides could be isolated form these cells expressing HLA-B35 subytypes, hmH antigens are thought to be conserved among populations.
1.我们发现人类白细胞抗原-B35分子的组装速度比人类白细胞抗原-B51分子的组装速度快。可以推测,这些HLAI类分子与多肽结合亲和力的不同导致了结合率的不同。为了研究多肽与人类白细胞抗原I类分子的结合,我们用转人类白细胞抗原I类基因的S细胞建立了一种新的结合实验。对携带HLA-B35或B51锚定残基的多肽与这些人类白细胞抗原I类分子的结合分析表明,它们与人类白细胞抗原B51的亲和力明显弱于与人类白细胞抗原B35的亲和力。2.为了明确T细胞识别的自身多肽,我们试图分离出人类白细胞抗原B51同种异体反应性CTL识别的异构肽。在从纯化的HLA-B51分子中分离的多肽中,检测到一种TAP依赖的多肽可被一个同种异体反应性CTL克隆识别。这种方法对于抗原提呈和T细胞识别的研究是非常有用的。3.利用人类小组织相容(HMH)特异性CTL克隆研究了HMH抗原的多态和抗原提呈。CTL克隆对大部分表达HLA-B35的靶细胞有杀伤作用,而对表达HLA-B35亚型的细胞无杀伤作用。由于可以从表达HLA-B35亚型的细胞中分离到特定的HMH多肽,因此HMH抗原被认为在人群中是保守的。
项目成果
期刊论文数量(71)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Kristen Falk: "Peptide motifs of HLA-A1,-A11,-A31and-A33 molewles." Immunogenetics. 40. 238-241 (1994)
Kristen Falk:“HLA-A1、-A11、-A31 和-A33 分子的肽基序。”
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Masafumi Takiguchi: "The role of conserved residue in pocket A and polymorphic resiclue in pocket E of HLA-B^*35 in presentation of human minor histocoupatibility peptides to T cells." International Immunology. 6. 1345-1352 (1994)
Masafumi Takiguchi:“HLA-B^*35 口袋 A 中的保守残基和口袋 E 中的多态残基在将人类次要组织偶联肽呈递给 T 细胞中的作用。”
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Yoshifumi Beck: "Polymorphism of human minor histoumpatibility antigen:T cell recognition of humn minor histoumpabilility peptides presented by HLA-B35 subtype molewles" Jounal of Experimental Medicine. (印刷中).
Yoshifumi Beck:“人类次要组织相容性抗原的多态性:HLA-B35 亚型鼹鼠呈现的人类次要组织相容性肽的 T 细胞识别”实验医学杂志(正在出版)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Ann B.Hill: "Different rate of HLA class I assembly which are detemined by amino acid sequence in the alpha-2 domain." Immunogenetics.37. 95-101 (1993)
Ann B.Hill:“HLA I 类组装的不同速率由 alpha-2 结构域中的氨基酸序列决定。”
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Yoshifumi Beck: "Expression of human minor histocompatibility autigen on cultured kidney cells." European Journal of Immunology. 23. 467-472 (1993)
Yoshifumi Beck:“人次要组织相容性自闭原在培养肾细胞上的表达。”
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TAKIGUCHI Masafumi其他文献
HLA-B*51:01トランスジェニックマウスにおけるHIV-1変異体の選択
HLA-B*51:01 转基因小鼠中 HIV-1 突变体的选择
- DOI:
- 发表时间:
2011 - 期刊:
- 影响因子:0
- 作者:
SATO Yoshinori;NAGATA Sayaka;TAKIGUCHI Masafumi - 通讯作者:
TAKIGUCHI Masafumi
HLA-B*51:01トランスジェニックマウスにおけるエフェクターCD8T細胞の誘導
HLA-B*51:01 转基因小鼠中效应 CD8 T 细胞的诱导
- DOI:
- 发表时间:
2011 - 期刊:
- 影响因子:0
- 作者:
SATO Yoshinori;NAGATA Sayaka;TAKIGUCHI Masafumi - 通讯作者:
TAKIGUCHI Masafumi
HLA-B*51:01トランスジェニックマウスにおけるヒトT細胞の表現型解析
HLA-B*51:01转基因小鼠中人类T细胞的表型分析
- DOI:
- 发表时间:
2011 - 期刊:
- 影响因子:0
- 作者:
SATO Yoshinori;TAKIGUCHI Masafumi - 通讯作者:
TAKIGUCHI Masafumi
TAKIGUCHI Masafumi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TAKIGUCHI Masafumi', 18)}}的其他基金
A study of therapy and prevention in a Vietnamese cohort of HIV-1 infection
越南 HIV-1 感染队列的治疗和预防研究
- 批准号:
15H02658 - 财政年份:2015
- 资助金额:
$ 4.35万 - 项目类别:
Grant-in-Aid for Scientific Research (A)
A study of HIV-1 escape mutants selected by cellular immunity
细胞免疫选择的HIV-1逃逸突变体的研究
- 批准号:
20390134 - 财政年份:2008
- 资助金额:
$ 4.35万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Escape mechanisms of HIV-1 from HIV-1-specific CTLs
HIV-1 从 HIV-1 特异性 CTL 中逃逸的机制
- 批准号:
18390141 - 财政年份:2006
- 资助金额:
$ 4.35万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of personal vaccine for virus
开发针对病毒的个人疫苗
- 批准号:
10557034 - 财政年份:1998
- 资助金额:
$ 4.35万 - 项目类别:
Grant-in-Aid for Scientific Research (B).
Studies of T cell Recognition for Viral Antigen Epitopes
T细胞识别病毒抗原表位的研究
- 批准号:
10470088 - 财政年份:1998
- 资助金额:
$ 4.35万 - 项目类别:
Grant-in-Aid for Scientific Research (B).
Development of CTL induced vaccine using reverse immunogenetics.
使用反向免疫遗传学开发 CTL 诱导疫苗。
- 批准号:
06557022 - 财政年份:1994
- 资助金额:
$ 4.35万 - 项目类别:
Grant-in-Aid for Developmental Scientific Research (B)
Molecular Immunological Analyses of Recognition to T cell For Major and Minor Histocompatibility Antigens
T 细胞识别主要和次要组织相容性抗原的分子免疫学分析
- 批准号:
02670198 - 财政年份:1990
- 资助金额:
$ 4.35万 - 项目类别:
Grant-in-Aid for General Scientific Research (C)
相似海外基金
Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy - Supplement
定义实验性 AD 和 Tau 病中 MHC I 类限制性抗原呈递至 CD8 T 细胞 - 补充
- 批准号:
10836880 - 财政年份:2023
- 资助金额:
$ 4.35万 - 项目类别:
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation
靶向 MAL2 介导的内吞作用以增强肿瘤细胞抗原呈递
- 批准号:
10734324 - 财政年份:2023
- 资助金额:
$ 4.35万 - 项目类别:
Antigen presentation to the adaptive immune system in the choroid contributes to ocular autoimmune disease
脉络膜中的适应性免疫系统的抗原呈递导致眼部自身免疫性疾病
- 批准号:
10740465 - 财政年份:2023
- 资助金额:
$ 4.35万 - 项目类别:
Investigation of Target Protein Degradation and Its Effect on Enhancing Cancer-Specific Antigen Presentation by Quantitative Mass Spectrometry
通过定量质谱研究靶蛋白降解及其对增强癌症特异性抗原呈递的影响
- 批准号:
23K04971 - 财政年份:2023
- 资助金额:
$ 4.35万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Promoting cancer cells' antigen presentation for serving as better targets for T cell immunotherapy
促进癌细胞的抗原呈递,作为 T 细胞免疫治疗的更好靶点
- 批准号:
2885451 - 财政年份:2023
- 资助金额:
$ 4.35万 - 项目类别:
Studentship
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy
结直肠癌免疫治疗中靶向免疫蛋白酶体介导的抗原呈递
- 批准号:
10385926 - 财政年份:2022
- 资助金额:
$ 4.35万 - 项目类别:
Lipid Antigen Presentation as a Driver of T2D Inflammation
脂质抗原呈递作为 T2D 炎症的驱动因素
- 批准号:
10509043 - 财政年份:2022
- 资助金额:
$ 4.35万 - 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
- 批准号:
10704008 - 财政年份:2022
- 资助金额:
$ 4.35万 - 项目类别:
Sex Differences in lipid antigen presentation, impact of lipid antigen presentation on peripheral lipid metabolism
脂质抗原呈递的性别差异,脂质抗原呈递对外周脂质代谢的影响
- 批准号:
10818273 - 财政年份:2022
- 资助金额:
$ 4.35万 - 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
- 批准号:
10349397 - 财政年份:2022
- 资助金额:
$ 4.35万 - 项目类别: